Abbott Laboratories Forecasted to Post Q2 2018 Earnings of $0.71 Per Share (ABT)

Abbott Laboratories (NYSE:ABT) – Research analysts at Jefferies Group raised their Q2 2018 earnings estimates for shares of Abbott Laboratories in a research note issued to investors on Wednesday, April 18th. Jefferies Group analyst R. Denhoy now forecasts that the healthcare product maker will earn $0.71 per share for the quarter, up from their previous estimate of $0.69. Jefferies Group also issued estimates for Abbott Laboratories’ Q4 2018 earnings at $0.79 EPS, FY2018 earnings at $2.85 EPS and FY2019 earnings at $3.23 EPS.

How to Become a New Pot Stock Millionaire

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, April 18th. The healthcare product maker reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.01. Abbott Laboratories had a return on equity of 14.53% and a net margin of 1.67%. The company had revenue of $7.39 billion for the quarter, compared to analysts’ expectations of $7.28 billion. During the same period last year, the firm earned $0.48 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis.



A number of other equities analysts have also recently issued reports on ABT. Morgan Stanley upgraded Abbott Laboratories from an “equal weight” rating to an “overweight” rating and set a $67.00 target price on the stock in a report on Tuesday, January 2nd. JPMorgan Chase upgraded Abbott Laboratories from a “neutral” rating to an “overweight” rating and set a $60.00 target price on the stock in a report on Tuesday, January 2nd. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a report on Tuesday, January 2nd. Evercore ISI initiated coverage on Abbott Laboratories in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $64.00 target price on the stock. Finally, Barclays restated a “buy” rating and issued a $66.00 target price on shares of Abbott Laboratories in a report on Monday, January 8th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $67.00.

Shares of NYSE ABT opened at $58.84 on Monday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.86 and a current ratio of 2.26. The firm has a market capitalization of $103,365.51, a P/E ratio of 23.54, a P/E/G ratio of 1.72 and a beta of 1.49. Abbott Laboratories has a 52-week low of $42.88 and a 52-week high of $64.60.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Stockholders of record on Friday, April 13th will be given a $0.28 dividend. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $1.12 annualized dividend and a dividend yield of 1.90%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 44.80%.

In related news, insider Roger Bird sold 8,262 shares of Abbott Laboratories stock in a transaction on Friday, March 9th. The stock was sold at an average price of $62.75, for a total transaction of $518,440.50. Following the completion of the sale, the insider now owns 58,574 shares of the company’s stock, valued at $3,675,518.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Stephen R. Fussell sold 56,401 shares of Abbott Laboratories stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $59.61, for a total value of $3,362,063.61. Following the sale, the insider now directly owns 184,884 shares of the company’s stock, valued at approximately $11,020,935.24. The disclosure for this sale can be found here. In the last three months, insiders have sold 124,261 shares of company stock valued at $7,559,987. Insiders own 0.74% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABT. Rowland & Co. Investment Counsel ADV acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth about $102,000. Icon Wealth Partners LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth about $102,000. SWS Partners acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth about $104,000. Cerebellum GP LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth about $133,000. Finally, We Are One Seven LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth about $138,000. 72.32% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Abbott Laboratories Forecasted to Post Q2 2018 Earnings of $0.71 Per Share (ABT)” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://stocknewstimes.com/2018/04/24/abbott-laboratories-forecasted-to-post-q2-2018-earnings-of-0-71-per-share-abt.html.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply